与万古霉素和替考拉宁相比，糖肽类抗生素LY333328的体外活性评估。

Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.

作者信息

Harland S, Tebbs S E, Elliott T S

机构信息

Department of Microbiology, University Hospital Birmingham NHS Trust, Queen Elizabeth Hospital, Edgbaston, UK.

出版信息

J Antimicrob Chemother. 1998 Feb;41(2):273-6. doi: 10.1093/jac/41.2.273.

DOI:10.1093/jac/41.2.273

PMID:9533471

Abstract

The in-vitro activity of a new glycopeptide antibiotic, LY333328, was compared with vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, vancomycin and teicoplanin resistant enterococci, and vancomycin sensitive and resistant enterococci. MIC, MBC, and time-kill kinetics were determined for each agent. LY333328 displayed similar or improved MIC/MBC values in comparison with vancomycin and teicoplanin. Time-kill kinetics for LY333328 demonstrated significantly improved bactericidal activity against the isolates. These findings suggest that LY333328 has improved in-vitro activity over vancomycin and teicoplanin against a range of gram-positive organisms.

摘要

将一种新型糖肽类抗生素LY333328的体外活性与万古霉素和替考拉宁进行了比较，受试菌株包括金黄色葡萄球菌临床分离株、凝固酶阴性葡萄球菌、耐万古霉素和替考拉宁的肠球菌以及对万古霉素敏感和耐药的肠球菌。测定了每种药物的MIC、MBC和时间杀菌动力学。与万古霉素和替考拉宁相比，LY333328的MIC/MBC值相似或有所改善。LY333328的时间杀菌动力学表明，其对受试菌株的杀菌活性显著提高。这些发现表明，LY333328在体外对一系列革兰氏阳性菌的活性比万古霉素和替考拉宁有所提高。